BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Forlano R, Mullish BH, Dhar A, Goldin RD, Thursz M, Manousou P. Liver function tests and metabolic-associated fatty liver disease: Changes in upper normal limits, does it really matter? World J Hepatol 2021; 13(12): 2104-2112 [PMID: 35070011 DOI: 10.4254/wjh.v13.i12.2104]
URL: https://www.wjgnet.com/1007-9327/full/v13/i12/2104.htm
Number Citing Articles
1
Satu Korpimäki, Suvi P Rovio, Markus Juonala, Nina Hutri-Kähönen, Terho Lehtimäki, Tomi P Laitinen, Päivi Tossavainen, Eero Jokinen, Britt-Marie Loo, Satu Männistö, Tuija Tammelin, Atte Haarala, Heikki Aatola, Gaber Komar, Jorma Viikari, Olli Raitakari, Mika Kähönen, Katja Pahkala. Nonalcoholic Fatty Liver Disease Incidence and Remission and Their Predictors During 7 Years of Follow-up Among FinnsThe Journal of Clinical Endocrinology & Metabolism 2023; 109(1): e291 doi: 10.1210/clinem/dgad418
2
Roberta Forlano, Giordano Sigon, Benjamin H. Mullish, Michael Yee, Pinelopi Manousou. Screening for NAFLD—Current Knowledge and ChallengesMetabolites 2023; 13(4): 536 doi: 10.3390/metabo13040536
3
Roberta Forlano, Mathuri Sivakumar, Benjamin H. Mullish, Pinelopi Manousou. Gut Microbiota—A Future Therapeutic Target for People with Non-Alcoholic Fatty Liver Disease: A Systematic ReviewInternational Journal of Molecular Sciences 2022; 23(15): 8307 doi: 10.3390/ijms23158307
4
Roberta Forlano, Tijana Stanic, Sahan Jayawardana, Benjamin Harvey Mullish, Michael Yee, Elias Mossialos, Robert Goldin, Salvatore Petta, Emmanouil Tsochatzis, Mark Thursz, Pinelopi Manousou. A prospective study on the prevalence of MASLD in people with type‐2 diabetes in the community. Cost effectiveness of screening strategiesLiver International 2024; 44(1): 61 doi: 10.1111/liv.15730
5
R. Forlano, L. Martinez-Gili, P. Takis, J. Miguens-Blanco, T. Liu, E. Triantafyllou, C. Skinner, R Loomba, M. Thursz, J. R. Marchesi, B.H. Mullish, P. Manousou. Disruption of gut barrier integrity and host–microbiome interactions underlie MASLD severity in patients with type-2 diabetes mellitusGut Microbes 2024; 16(1) doi: 10.1080/19490976.2024.2304157
6
Roberta Forlano, Pinelopi Manousou. Another arrow in the NASH quiver?The Lancet Gastroenterology & Hepatology 2023; 8(2): 96 doi: 10.1016/S2468-1253(22)00383-1
7
Amedeo Lonardo. Alanine aminotransferase predicts incident steatotic liver disease of metabolic etiology: Long life to the old biomarker!World Journal of Gastroenterology 2024; 30(24): 3016-3021 doi: 10.3748/wjg.v30.i24.3016
8
Heba Ahmed Osman, Sawsan M. A. Abuhamdah, Mohammed H. Hassan, Abdelkader Ahmed Hashim, Abdelazeem E. Ahmed, Sameh Salaheldin Elsayed, Samer A. El-Sawy, Mostafa A. Gaber, Marwa Abdelhady. NLRP3 inflammasome pathway involved in the pathogenesis of metabolic associated fatty liver diseaseScientific Reports 2024; 14(1) doi: 10.1038/s41598-024-69764-y